2022-501097-19-00招募中2 期
A randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Galapagos
- 入组人数
- 32
- 试验地点
- 29
- 主要终点
- Total improvement score [TIS] according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria at Week 24. Open Label Extension : Frequency and severity of TEAEs, treatment-emergent SAEs, and TEAEs leading to treatment discontinuation (over time up to Week 52).
研究概览
简要总结
To evaluate the efficacy of GLPG3667 compared to placebo on the signs and symptoms of dermatomyositis. Open Label Extension: to evaluate the safety and tolerability of GLPG3667 150 mg q.d. in subjects with DM.
研究设计
- 分配方式
- Randomized
- 主要目的
- Double blind treatment period
- 盲法
- Double (Analyst, Monitor, Carer, Investigator, Subject)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Female or male subjects from 18 to 75 years of age inclusive, on the date of signing the informed consent form.
- •Subject has probable or definite DM in accordance with the ACR/EULAR criteria for at least 3 months.
- •Subject with dermatomyositis diagnosed in the 3 years prior to screening must have undergone cancer screening (according to local standard of care or applicable guidelines) within 1 year prior to screening.
- •Subject must present objective evidence of active disease as defined by fulfilling 1 of the criteria below (as confirmed by the sponsor): dermatomyositis rash as defined by m-CDASI-A >= 6 at screening, or creatinine kinase > 4x ULN at screening, or muscle biopsy evidence of active disease within 3 months prior to screening (as defined as presence of active inflammation in muscle biopsy), or muscle magnetic resonance imaging showing active inflammation (edema) of the proximal skeletal muscles within 3 months prior to screening, or electromyography showing acute changes, such as spontaneous activity and myopathic changes not explained by other diseases, within 3 months prior to screening, or any other clinical evidence of active disease as confirmed by the steering committee.
- •Subject has reduced muscle strength (defined as Manual Muscle Test-8 < 142/150) and at least 2 additional abnormal core set measurements out of the following 5 at screening: Physician’s Global Disease Activity score > 2/10 cm on the visual analog scale and/or Patient’s Global Disease Activity score > 2/10 cm on the visual analog scale (VAS), and/or extra-muscular disease activity > 2/10 cm on VAS, and/or Health Assessment Questionnaire-Disability Index score > 0.25, and/or elevated muscle enzymes (e.g. aldolase, CK, ALT, AST, and lactate dehydrogenase) with at least 1 muscle enzyme > 1.5x ULN.
- •Subject previously demonstrated failure to or intolerance to first-line treatment (defined as oral corticosteroid[s] and at least 1 immunosuppressant/hydroxychloroquine) OR active disease despite treatment with first-line drugs. Currently, the subject is receiving maximum 3 treatments for dermatomyositis (oral corticosteroid[s] and/or allowed immunosuppressant[s]/hydroxychloroquine) for at least 3 months and is on a stable dose (defined as no change in dose, type of administration, or dose regimen) for at least 4 weeks prior to screening and during screening within maximum allowed doses as specified in the protocol.
- •Open Label Extension : The ICF has been signed at the screening visit (see inclusion criteria #1 and #9). Subjects must meet both of the following inclusion criteria at Visit 8 to be eligible for participation in the OLE period of the study: subject who may benefit from open-label treatment with GLPG3667, according to the investigator’s judgment. Female or male subjects who completed the 24-week double-blind treatment period on IP.
排除标准
- •Subject has cancer-associated myositis (defined as myositis diagnosed within 2 years of cancer diagnosis with the exception of basal cell carcinoma, squamous cell carcinoma of the skin, or in situ uterine cervical carcinoma that has been excised and cured).
- •Subject has other causes of myositis (e.g. connective tissue disease) associated dermatomyositis (DM), polymyositis, juvenile DM, inclusion body myositis, or necrotizing idiopathic inflammatory myopathies (with or without rash) with the exception of overlap with secondary Sjogren's syndrome.
- •Subject has permanent muscle weakness due to muscle damage (e.g. subject is wheelchair bound or has significant muscle atrophy on MRI) or a non-DM cause (drug-induced myopathy, including glucocorticoid-induced myopathy as primary cause of muscle weakness), according to investigator’s judgement.
- •Subject has taken any prohibited therapies within the defined washout periods before screening, and during screening as listed in the protocol.
- •Open Label Extension : Subjects meeting one or more of the criteria at Visit 8 as defined in the protocool, cannot be selected for the OLE period of this clinical study.
- •Subject has total bilirubin >1.5x ULN; subjects with an isolated increase in total bilirubin <3 x ULN due to Gilbert’s Syndrome, with normal direct bilirubin, can be enrolled in the OLE period.
- •Subject has AST or ALT >1.5 x ULN (hepatic injury), or AST or ALT >=5 x ULN if judged to be of muscular origin (and confirmed by the steering committee) at Visit 7 and Visit 8.
结局指标
主要结局
Total improvement score [TIS] according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria at Week 24. Open Label Extension : Frequency and severity of TEAEs, treatment-emergent SAEs, and TEAEs leading to treatment discontinuation (over time up to Week 52).
Total improvement score [TIS] according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria at Week 24. Open Label Extension : Frequency and severity of TEAEs, treatment-emergent SAEs, and TEAEs leading to treatment discontinuation (over time up to Week 52).
次要结局
- At week 24 - - Proportion of subjects with at least minimal improvement according to the ACR/EULAR criteria (defined as TIS of >= 20 points) at Week 24. - Change from baseline in modified-Cutaneous DM Disease Area and Severity Index Activity Score (m-CDASI-A). - Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) - Change from baseline in the manual muscle test (MMT-8)
- Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuation (over time up to Week 24).
- Estimated GLPG3667 maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC), and trough plasma concentration (Ctrough) at steady-state.
研究者
Galapagos Medical Information
Scientific
Galapagos
研究点 (29)
Loading locations...
相似试验
招募中
2 期
A Phase 1/2 Study to Assess AMG 732 in Healthy Subjects and Subjects with Thyroid Eye DiseaseThyroid Eye Disease2024-514110-12-00Amgen Inc.16
招募中
3 期
A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and female participants aged at least 18 years (STYLE 1)2024-514737-37-00Sanofi-Aventis Recherche & Developpement77
招募中
1 期
Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or EczemaAtopic Dermatitis2025-520514-64-00Rubedo Life Sciences Italy S.R.L.40
招募中
3 期
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA)Fibrodysplasia Ossificans Progressiva2023-508350-26-00Regeneron Pharmaceuticals Inc.24
已完成
3 期
SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy2022-502697-16-00Regentree LLC70